BriaCell Therapeutics (BCTX) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
BriaCell Therapeutics (BCTX) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 69.2% versus a loss of 87.4%. Over five years, BCTX leads with a -95.2% price change compared with -100.0% for RNAZ. BriaCell Therapeutics is the larger company by market cap ($34.0 million vs $31.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | RNAZ |
|---|---|---|
| Share price | $3.91 | $1.86 |
| Market cap | $34.02M | $31.49M |
| 1-day change | -0.13% | +8.77% |
| YTD return | -44.87% | -72.77% |
| 1-year return | -69.18% | -87.42% |
| 5-year return | -95.21% | -100.00% |
| EPS (TTM) | $-0.92 | $-52.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.68 | $15.94 |
| 52-week low | $2.60 | $1.52 |
| Distance from 52-week high | -73.37% | -88.33% |
| Average volume | 278.91K | 50.19K |
| Shares outstanding | 8.70M | 16.93M |
| Employees | — | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCTX has outperformed RNAZ by 18.2 percentage points over the past year.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
BCTX vs RNAZ FAQ
Which is bigger, BriaCell Therapeutics or TransCode Therapeutics?
BriaCell Therapeutics (BCTX) is larger, with a market capitalization of $34.02M compared with $31.49M for TransCode Therapeutics (RNAZ).
Which stock has performed better over the past year, BCTX or RNAZ?
BCTX returned -69.18% over the past 12 months, compared with -87.42% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.